Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA

Emily P. Thi, Chad Mire, Raul Ursic-Bedoya, Joan B. Geisbert, Amy C H Lee, Krystle N. Agans, Marjorie Robbins, Daniel J. Deer, Karla A. Fenton, Ian MacLachlan, Thomas Geisbert

Research output: Contribution to journalArticle

44 Scopus citations

Abstract

Marburg virus (MARV) and the closely related filovirus Ebola virus cause severe and often fatal hemorrhagic fever (HF) in humans and nonhuman primates with mortality rates up to 90%. There are no vaccines or drugs approved for human use, and no postexposure treatment has completely protected nonhuman primates against MARV-Angola, the strain associated with the highest rate of mortality in naturally occurring human outbreaks. Studies performed with other MARV strains assessed candidate treatments at times shortly after virus exposure, before signs of disease are detectable. We assessed the efficacy of lipid nanoparticle (LNP) delivery of anti-MARV nucleoprotein (NP)-targeting small interfering RNA (siRNA) at several time points after virus exposure, including after the onset of detectable disease in a uniformly lethal nonhuman primate model of MARV-Angola HF. Twenty-one rhesus monkeys were challenged with a lethal dose of MARV-Angola. Sixteen of these animals were treated with LNP containing anti-MARV NP siRNA beginning at 30 to 45 min, 1 day, 2 days, or 3 days after virus challenge. All 16 macaques that received LNP-encapsulated anti-MARV NP siRNA survived infection, whereas the untreated or mock-treated control subjects succumbed to disease between days 7 and 9 after infection. These results represent the successful demonstration of therapeutic anti-MARV-Angola efficacy in nonhuman primates and highlight the substantial impact of an LNP-delivered siRNA therapeutic as a countermeasure against this highly lethal human disease.

Original languageEnglish (US)
Article number250ra116
JournalScience Translational Medicine
Volume6
Issue number250
DOIs
StatePublished - Aug 20 2014

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Thi, E. P., Mire, C., Ursic-Bedoya, R., Geisbert, J. B., Lee, A. C. H., Agans, K. N., Robbins, M., Deer, D. J., Fenton, K. A., MacLachlan, I., & Geisbert, T. (2014). Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA. Science Translational Medicine, 6(250), [250ra116]. https://doi.org/10.1126/scitranslmed.3009706